Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herceptin Less-Frequent Dosing Is Preferred For Early-Stage Breast Cancer, NICE Says

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K.’s NICE supports adoption of three-week interval dosing for trastuzumab for early-stage HER2-positive breast cancer.

You may also be interested in...



NICE Sends Out Cost Warning By Flatly Rejecting Kadcyla On Price

Not inspired by its clinical effectiveness, NICE has said it will not recommend Roche's “over-priced” Kadcyla for breast cancer.

Herceptin sBLA Submitted For Early-Stage Use

A supplemental BLA for an early adjuvant breast cancer indication for Herceptin will have a mid-August user fee date, if granted priority review

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.

Topics

UsernamePublicRestriction

Register

PS064307

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel